New Zealand Pig Islet Trial One Step Closer to Reality


By: Linda von Wartburg

Eight New Zealanders with type 1 diabetes are hoping to receive pig islet transplantations by the end of the year, now that the company Living Cell Technologies (LCT) has surmounted the first of three regulatory hurdles in pursuit of permission for a twelve-month trial in New Zealand.

This comes upon the heels of a similar year-long Phase I/IIA clinical trial that is primed to begin in Moscow, Russia. The islet cells (called “DiabeCells” by LCT) will be encapsulated in alginate, a gelatinous seaweed extract that allows the islets to release insulin in response to blood glucose, but prevents the body’s antibodies from reaching the islets. As a result, toxic immuno-suppressants theoretically won’t be necessary. LCT will be using islet cells from newborn piglets of a special bio-certified pig herd that was isolated on Auckland Island for 200 years.

In recent news, it was found that a patient who had been injected with similar cells in 1996 was still getting a little insulin from the cells ten years afterward.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.